SmartSpace Software plc

Software and Services



UK Equity Research 10 May 2021

James Wood | Analyst | Canaccord Genuity Ltd (UK) | jwood@cgf.com | 44.20.7523.8399

ARR continues to build through Q1

Canaccord Genuity view

Today's FY results to 31 January 2021 were consistent with the expectations set out in our recent initiation "A fast-growth, high margin SaaS value opportunity". Exit ARR (£3.0m, +50% y/y) was marginally ahead of our £2.9m estimate while revenue of £4.6m, LBITDA of £2.1m and net cash of £4.1m were in line as SmartSpace continued to build positive momentum following its recent pivot to a pure play, fast growth SaaS business.

Our investment case sees SmartSpace expanding ARR by 68% CAGR over the next three years to £14.2m through organic growth of its SwipedOn (SO) and Space Connect (SC) platforms as SaaS drives a higher quality and strongly profitable mix. We believe the roadmap out of lockdown will be a key driver of growth as companies ensure their workspaces offer flexible, productive and COVID-secure environments with optionality to reduce footprint. We note encouraging progress through Q1'22E:

- SO ARPU up 8.3% to NZ\$99.3 with a price increase for new customers from 1 February a major factor. ARR rose NZ\$0.5m (+9.1%) to NZ\$5.7m vs a NZ\$1.6m increase through FY21.
- SO added 318 locations (1.77x locations per customer) reflecting a focus on higher value, stickier deals with enterprise-level customers. Locations per customer were 1.42x in FY21 and 1.36x in FY20.
- Engagement has begun with the first SO Desks customers.
- The SC sales pipeline has grown from £0.6m in February to £1.2m at the end of April driven by Return to Office channel partner promotions. SC is now approaching 40 customers with average ARR of £10k each.
- Evoko Naso revenues have been booked every month since the December 2020 launch.

We reiterate our BUY rating and 220p target price.

Strong progress at SwipedOn

SO performed strongly through FY21. Customers increased 21.5% to 4,735 at 31 January with locations up 27.7% to 6,741. A focus on higher value mid-market customers helped ARPU expand 18% to NZ\$91.9 vs NZ\$78 (FY20). This includes an Australian Court Service (68 locations), an Australian Housebuilder (58 locations) and a Canadian Restaurant brand (49 locations). A focus on centralised deals also helped SO secure revenue expansion across several large existing accounts including Access Information Systems, DHL, XPO and Vestas.

Space Connect opportunity building

SC provides two strategically important advantages. The first is it enables a white label software deal with Evoko for their next-generation Naso panel which has the potential to generate material licence and SaaS-based revenues. The first revenues have begun to be recognised while the prospect list includes several international brands. The second is it allows an agile mid-market growth strategy through the development of indirect sales channels. Agreements with 22 global resellers are now in place including Softcat which has already delivered significant ARR.

Reiterate BUY and 220p target price; implied upside of 54%


We make no changes to our estimates on which SmartSpace trades on an EV/Sales of 5.3x for FYJan22E falling to 3.3x for FYJan23E. We believe the current share price offers an attractive opportunity to participate in this high-margin, high-double-digit growth story. We reiterate our BUY rating with a 220p target price based on 5.5x FYJan23E EV/Sales, which is in line with the blended CY21E/22E average from our UK SaaS/software peer group and supported by DCF.

| Rating | Price Target |
|-----------|---------------|
| BUY | 220p |
| unchanged | unchanged |
| SMRT-AIM | Price 143p |

Market Data

| 52-Week Range (p): | 20 - 155 |
|------------------------|----------|
| Avg Daily Vol (M) : | 0.06 |
| Market Cap (£M): | 41.1 |
| Shares Out. (M) : | 28.9 |
| Enterprise Value (£M): | 36.8 |
| | |

| FYE Jan | 2021A | 2022E | 2023E | 2024E |
|-------------------------|--------|--------|-------|-------|
| Sales (£M) | 4.6 | 7.0 | 10.5 | 15.0 |
| EBITDA (£M) | (2.1) | (0.7) | 1.3 | 4.6 |
| PBT Adj (£M) | (2.4) | (0.9) | 1.0 | 4.4 |
| EPS Adj&Dil (p) | (11.8) | (2.9) | 2.8 | 12.1 |
| EV/Sales (x) | 7.8 | 5.3 | 3.3 | 2.0 |
| EV/EBITDA (x) | (17.1) | (55.5) | 28.0 | 6.6 |
| P/E (x) | (12.1) | (48.8) | 50.4 | 11.9 |
| Equity FCF Yield (%) | (5.4) | 0.5 | 4.6 | 11.0 |
| Net Debt (Cash) (£M) | (4) | (5) | (6) | (11) |
| | | | | |



Source: FactSet

Priced as of close of business 7 May 2021

The provision of cloud-based SaaS software solutions focused on space and workplace management.

Canaccord Genuity Limited is authorized and regulated by the Financial Conduct Authority (FCA). This is non-independent research and a marketing communication under the Market Abuse Regulation and the FCA Conduct of Business rules. For purposes of FINRA Rule 2241, this is considered third party research.



Company summary


Company Description

SmartSpace Software is a fast growing, SaaS-based provider of visitor management and space optimisation solutions, principally for the SME and midmarket. The group operates two cloud-based platforms (SwipedOn and Space Connect) which can be easily self-deployed, allowing customers to create safe and flexible workplace environments to manage building occupancy. In addition, real-time and predictive analytics help clients make informed decisions to improve the efficiency of a workspace and support real estate rationalisation strategies.


Key Competitors

Key competitors in the mid- market include Condeco, Teem/iOffice and Cloudbooking. In the SME market, competitors include Envoy, ProxyClick, Sign In App, Traction Guest and Sine.

Customers by geography







Revenue and Gross Profit



Interest cover (x)

(15.2)

(124.9)

(131.3)

Source: Company reports, Canaccord Genuity estimates

| Valuation | Jan- 19 | Jan-20 | Jan- 21 | Jan-22E | Jan-23E | Jan-24E |
|--|--|---|---|--|---|---|
| EV/Sales | 8.1x | 7.5x | 7.8x | 5.3x | 3.3x | 2.0x |
| EV/EBITDA | - 13.7x | -22.9x | - 17.1x | -55.5x | 28.0x | 6.6x |
| P/E | - 15.6x | -4.9x | - 12.1x | -48.8x | 50.4x | 11.9x |
| Price/book | 1.4x | 2.3x | 2.5x | 2.6x | 2.5x | 2.1x |
| Dividend yield | - | - | - | - | - | - |
| FCF yield | (17.7%) | (19.2%) | (5.4%) | 0.5% | 4.6% | 11.0% |
| P&L (£m) | Jan- 19 | Jan-20 | Jan- 21 | Jan-22E | Jan-23E | Jan-24E |
| Exit ARR | 1.0 | 2.0 | 3.0 | 5.5 | 9.5 | 14.2 |
| Sales | 3.0 | 5.1 | 4.6 | 7.0 | 10.5 | 15.0 |
| Gross Profit | 1.1 | 2.1 | 2.7 | 4.8 | 8.2 | 12.3 |
| EBITDA | (1.8) | (1.7) | (2.1) | (0.7) | 1.3 | 4.6 |
| Adj. PBT | (1.9) | (2.0) | (2.4) | (0.9) | 1.0 | 4.4 |
| Tax | 1.0 | 0.4 | 0.5 (1.9) | (0.9) | (0.2) 0.8 | (0.8) 3.6 |
| Continuing adj. net income Discontinued | (0.8) (1.1) | (1.6) (5.3) | (1.9) | 0.0 | 0.0 | 0.0 |
| Adj. Net Income | (1.1) | (6.9) | (3.3) | (0.9) | 0.0 | 3.6 |
| EPS (adj. FD) (p) | (9.2) | (29.1) | (11.8) | (2.9) | 2.8 | 12.1 |
| DPS | (0.2) | (20.1) | (11.0) | (2.0) | 2.0 | - |
| Growth | Jan- 19 | Jan-20 | Jan- 21 | Jan-22E | Jan-23E | Jan-24E |
| Sales (%) | (51.8) | 71.7 | (8.9) | 50.3 | 51.2 | 42.5 |
| EBITDA (%) | (921.6) | (4.5) | 26.8 | (68.8) | (288.8) | 271.4 |
| PBT (%) | 1,316.7 | 5.4 | 21.7 | (63.8) | (220.3) | 325.0 |
| EPS (%) | (190.1) | 216.3 | (59.4) | (75.2) | (196.9) | 325.0 |
| DPS (%) | _ | _ | | _ | _ | _ |
| 2. 0 (70) | | | | | | |
| Cash Flow (£m) | Jan- 19 | Jan-20 | Jan- 21 | Jan-22E | Jan-23E | Jan-24E |
| , , | Jan-19 (2.0) | Jan-20 (2.4) | Jan-21 (2.7) | Jan-22E (1.2) | Jan-23E 0.8 | Jan-24E 4.2 |
| Cash Flow (£m) | | | | (1.2) 0.4 | | |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other | (2.0) 0.1 (1.9) | (2.4) 0.2 (3.8) | (2.7) 0.4 0.1 | (1.2) 0.4 0.1 | 0.8 0.4 0.1 | 4.2 0.4 0.1 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements | (2.0) 0.1 (1.9) 0.4 | (2.4) 0.2 (3.8) 0.0 | (2.7) 0.4 0.1 0.5 | (1.2) 0.4 0.1 1.5 | 0.8 0.4 0.1 1.5 | 4.2 0.4 0.1 1.6 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax | (2.0) 0.1 (1.9) 0.4 (0.1) | (2.4) 0.2 (3.8) 0.0 0.1 | (2.7) 0.4 0.1 0.5 0.4 | (1.2) 0.4 0.1 1.5 (0.0) | 0.8 0.4 0.1 1.5 (0.2) | 4.2 0.4 0.1 1.6 (0.9) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) | (2.7) 0.4 0.1 0.5 0.4 (0.7) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) | 0.8 0.4 0.1 1.5 (0.2) (0.6) | 4.2 0.4 0.1 1.6 (0.9) (0.8) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) | (2.7) 0.4 0.1 0.5 0.4 (0.7) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) | 0.8 0.4 0.1 1.5 (0.2) (0.6) | 4.2 0.4 0.1 1.6 (0.9) (0.8) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 0.0 (0.1) | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 0.0 (0.1) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 0.0 6.4 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 0.0 (0.1) | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 0.0 6.4 7.6 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 0.0 (0.1) 1.8 6.4 | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 10.8 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 10.8 Jan-24E |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) Non current assets | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 14.3 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 12.2 3.7 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 13.5 5.7 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E 13.7 6.3 | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E 13.9 8.2 | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 10.8 Jan-24E 14.3 12.7 |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) Non current assets Current assets | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 10.8 Jan-24E |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) Non current assets Current assets Non current liabilities | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 14.3 12.8 (0.4) | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 12.2 3.7 (0.1) | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 13.5 5.7 (0.5) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E 13.7 6.3 (0.5) | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E 13.9 8.2 (0.5) | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 10.8 Jan-24E 14.3 12.7 (0.5) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) Non current assets Current assets Non current liabilities Current liabilities | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 14.3 12.8 (0.4) | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 12.2 3.7 (0.1) (2.3) | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 13.5 5.7 (0.5) (2.4) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E 13.7 6.3 (0.5) | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E 13.9 8.2 (0.5) (5.1) | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 10.8 Jan-24E 14.3 12.7 (0.5) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) Non current assets Current assets Non current liabilities Current liabilities Held for sale | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 14.3 12.8 (0.4) (3.3) | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 12.2 3.7 (0.1) (2.3) 4.4 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 13.5 5.7 (0.5) (2.4) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E 13.7 6.3 (0.5) (3.8) | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E 13.9 8.2 (0.5) (5.1) | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 0.0 (0.1) 4.4 10.8 Jan-24E 14.3 12.7 (0.5) (6.6) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) Non current assets Current assets Non current liabilities Current liabilities Held for sale | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 14.3 12.8 (0.4) (3.3) | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 12.2 3.7 (0.1) (2.3) 4.4 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 13.5 5.7 (0.5) (2.4) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E 13.7 6.3 (0.5) (3.8) | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E 13.9 8.2 (0.5) (5.1) | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 0.0 (0.1) 4.4 10.8 Jan-24E 14.3 12.7 (0.5) (6.6) |
| Cash Flow (£m) EBIT Depreciation & amortisation Exceptionals/other Working capital movements Interest & Tax Capex Free cash flow Acquisitions/disposals Share issues Dividends Other Movement in net cash Net cash/(debt) Balance Sheet (£m) Non current assets Current assets Non current liabilities Current liabilities Held for sale Net Assets | (2.0) 0.1 (1.9) 0.4 (0.1) (2.1) (5.6) 12.0 0.0 0.0 6.4 7.6 Jan-19 14.3 12.8 (0.4) (3.3) | (2.4) 0.2 (3.8) 0.0 0.1 (2.0) (7.7) (0.8) 3.2 0.0 (0.0) (5.4) 2.2 Jan-20 12.2 3.7 (0.1) (2.3) 4.4 | (2.7) 0.4 0.1 0.5 0.4 (0.7) (2.2) 4.2 0.0 0.0 (0.1) 1.9 4.1 Jan-21 13.5 5.7 (0.5) (2.4) | (1.2) 0.4 0.1 1.5 (0.0) (0.6) 0.2 0.4 0.0 0.0 (0.1) 0.5 4.6 Jan-22E 13.7 6.3 (0.5) (3.8) - 15.7 | 0.8 0.4 0.1 1.5 (0.2) (0.6) 1.9 0.0 0.0 (0.1) 1.8 6.4 Jan-23E 13.9 8.2 (0.5) (5.1) - 16.5 | 4.2 0.4 0.1 1.6 (0.9) (0.8) 4.5 0.0 0.0 (0.1) 4.4 10.8 Jan-24E 14.3 12.7 (0.5) (6.6) - 20.0 |

48.6

237.0



Appendix: Important Disclosures

For the purposes of UK regulation Canaccord Genuity Limited produces non-independent research which is a marketing communication under the Financial Conduct Authority (FCA) Conduct of Business Rules and an investment recommendation under the Market Abuse Regulation and is not prepared in accordance with legal requirements designed to promote the independence of investment research, nor is it subject to any prohibition on dealing ahead of the dissemination of investment research. However, Canaccord Genuity Limited does have procedures in place to identify and manage conflicts of interest which may arise in the production of non-independent research, which include preventing dealing ahead and Information Barrier procedures. Further detail on Canaccord Genuity Limited's conflict management policies can be accessed at the following website (provided as a hyperlink if this report is being read electronically): http://www.canaccordgenuity.com/en/cm/SiteInformation/Disclaimer/UK-Disclosures/.

Analyst Certification

Each authoring analyst of Canaccord Genuity Limited whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research.

Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Sector Coverage

Individuals identified as "Sector Coverage" cover a subject company's industry in the identified jurisdiction, but are not authoring analysts of the report.

Specialist Salespeople

Specialist Salespeople may be listed on research reports for contact purposes. They are not authoring analysts of the report.

Investment Recommendation

Date and time of first dissemination: May 10, 2021, 02:02 ET Date and time of production: May 10, 2021, 02:02 ET

Target Price / Valuation Methodology:

SmartSpace Software plc - SMRT

Given the shape of revenue and margin mix that is expected to flow from SaaS within our forecasts we believe FY22E and FY23E are the most relevant proxies on which to base valuation, given they fully capture the expected growth from both SwipedOn and Space Connect. Applying the blended average (CY21E/CY22E) EV/Sales multiple from our UK peer group (5.5x) to our FYJan23E SmartSpace forecast suggests a valuation of 220p/share, at which we set our price target. In addition, we see support from our DCF analysis (227p/share) and recent M&A.

Risks to achieving Target Price / Valuation:

SmartSpace Software plc - SMRT

- The early stage of the transition to a SaaS-based model brings execution risk.
- A significant part of the growth story is dependent on the success of Evoko Naso. While our forecasts are based on conservative assumptions with regards to unit sales and SaaS participation, we recognise that there is material sensitivity to flexes in the model (to the upside as well as to the downside).
- The Workplace Management Software vertical is a highly competitive growth market in which SmartSpace remains a small participant. Barriers to entry are therefore low and a well-funded competitor may invest in margin to take share.
- The fast pace of technological change means that functionality may quickly become outdated, requiring significant investment in product development.
- A macroeconomic slowdown, or subsequent reintroduction of any lockdown policy in key geographies may slow a return to the workplace, delay corporate investment plans or reduce demand for flexible workspace technologies.
- While many commentators anticipate a hybrid workplace model moving forward, if corporates instead adopt a work-from-home model the potential TAM could decline.
- The group is exposed to NZD (SwipedOn) and EUR (Evoko). While we have adopted FX rates 2-3% ahead of spot, a strong appreciation of GBP could negatively impact revenue and profitability.
- Key person risk, albeit the founders of SwipedOn and Space Connect each hold significant shareholdings and remain as MDs of the respective businesses.



Distribution of Ratings:

Global Stock Ratings (as of 05/10/21)

| Rating | Coverag | Coverage Universe | |
|-----------------|---------|-------------------|--------|
| | # | % | % |
| Buy | 604 | 64.12% | 41.06% |
| Hold | 169 | 17.94% | 21.89% |
| Sell | 13 | 1.38% | 30.77% |
| Speculative Buy | 143 | 15.18% | 68.53% |
| | 942* | 100.0% | |

^{*}Total includes stocks that are Under Review

Canaccord Genuity Ratings System

BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months.

HOLD: The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months.

SELL: The stock is expected to generate negative risk-adjusted returns during the next 12 months.

NOT RATED: Canaccord Genuity does not provide research coverage of the relevant issuer.

"Risk-adjusted return" refers to the expected return in relation to the amount of risk associated with the designated investment or the relevant issuer.

Risk Qualifier

SPECULATIVE: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the stock may result in material loss.

12-Month Recommendation History (as of date same as the Global Stock Ratings table)

A list of all the recommendations on any issuer under coverage that was disseminated during the preceding 12-month period may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures-mar.canaccordgenuity.com/EN/Pages/default.aspx

Required Company-Specific Disclosures (as of date of this publication)


SmartSpace Software plc currently is, or in the past 12 months was, a client of Canaccord Genuity or its affiliated companies. During this period, Canaccord Genuity or its affiliated companies provided investment banking services to SmartSpace Software plc.

In the past 12 months, Canaccord Genuity or its affiliated companies have received compensation for Investment Banking services from SmartSpace Software plc .

Canaccord Genuity acts as corporate broker for SmartSpace Software plc and/or Canaccord Genuity or any of its affiliated companies may have an agreement with relating to the provision of Investment Banking services.

Canaccord Genuity or one or more of its affiliated companies is a market maker or liquidity provider in the securities of SmartSpace Software plc or in any related derivatives.

Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from SmartSpace Software plc in the next three months.





Required Company-Specific Disclosures (as of date of this publication)

Past performance

In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance.

Online Disclosures

Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@cgf.com. The reader may also obtain a copy of Canaccord Genuity's policies and procedures regarding the dissemination of research by following the steps outlined above.

General Disclaimers

See "Required Company-Specific Disclosures" above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, "Compendium Reports." "Canaccord Genuity" is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 80% owned by Canaccord Genuity Group Inc.

The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Limited, which is authorised and regulated by the Financial Conduct Authority (FCA).

With respect to research recommendations on issuers covered by a research analyst employed by Canaccord Genuity Limited, it is Canaccord Genuity Limited's policy that research analysts publish financial estimates, valuations, price targets and recommendations for all companies covered at least every six months and as soon as possible after all relevant events.

The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research.

The information contained in this research has been compiled by Canaccord Genuity Limited from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity Limited has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity's judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity's affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity Limited, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

Research Distribution Policy

Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity's customers who are entitled to receive the firm's research. In addition research may be distributed by the firm's sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity's customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent.

For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative.



Short-Term Trade Ideas

Research Analysts may, from time to time, discuss "short-term trade ideas" in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term 'Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or "Speculative Buy' could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity's research.

For Canadian Residents:

This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

For United Kingdom and European Residents:

This research is for persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 (or any analogous legislation) on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or Europe to retail clients, as defined under the rules of the Financial Conduct Authority.

For United States Persons:

This research is distributed by Canaccord Genuity Limited in the United States to "major US institutional investors", as defined under Rule 15a-6 promulgated under the US Securities Exchange Act of 1934, as amended, and as interpreted by the staff of the US Securities and Exchange Commission (SEC). This research is also distributed in the United States to other institutional investors by Canaccord Genuity LLC, who accepts responsibility for this research and its dissemination in the United States. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC.

Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

For Jersey, Guersney and Isle of Man Residents:

This research is sent to you by Canaccord Genuity Wealth (International) Limited ("CGWI") for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser.

CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc.

For Australian Residents:

This research is distributed in Australia by Canaccord Genuity Limited. Under ASIC Class Order (CO 03/1099), Canaccord Genuity Limited is exempt from the requirement to hold an Australian financial services licence for the provision of its financial services to you. Canaccord Genuity Limited is authorised and regulated by the Financial Conduct Authority under the laws of the United Kingdom which differ from Australian laws. This research is provided to you on the basis that you are a 'wholesale client' within the meaning of section 761G of the Corporations Act 2001 (Cth). To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in this research should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052.

For Hong Kong Residents:



This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request.

- Copyright © Canaccord Genuity Corp. 2021 Member IIROC/Canadian Investor Protection Fund
- Copyright © Canaccord Genuity Limited. 2021 Member LSE, authorized and regulated by the Financial Conduct Authority.
- Copyright © Canaccord Genuity LLC 2021 Member FINRA/SIPC
- Copyright © Canaccord Genuity (Australia) Limited. 2021 Participant of ASX Group, Chi-x Australia and of the NSX. Authorized and regulated by ASIC.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.

None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.